The Relative Clinical and Economic Value of Ipilimumab as First-Line Treatment of Metastatic Melanoma Versus Other Anti-Cancer Agents for Metastatic Diseases
Abstract
Authors
A.P. Abernethy S. Kotapati I. Gilloteau J. Karweit S. Wolfe